University of Nottingham
Prof. Philip Bath
Principal Investigator
University of Nottingham
University Park
NG7 2RD Nottingham
United Kingdom
PRECIOUS Team University of Nottingham
Institute presentation
The University is listed as 114 in the world rankings (33 in Europe, top 20 in UK, second in UK for businesses’ finding graduate recruits, world’s second greenest University) with 33,435 students (including students at the Malaysian and China campuses). In the UK 2021 Research Excellence Framework, the University ranked 7th for research power; >90% of staff were ranked “world-leading’ or ‘internationally excellent’. The Faculty of Medicine and Health Sciences hosts schools of Medicine, Nursing, and Veterinary Medicine. The Faculty hosts the UK-registered Nottingham Clinical Trials Services Unit, two NIHR Biomedical Research Units, and Cochrane Collaborative groups.
The Stroke Research Group has four principal investigators leading translational research encompassing preclinical models of stroke, phase I and II trials, phase III safety/efficacy trials, and late stage translation of research into practice. The Stroke Trials Unit is currently coordinating five trials:
Nottingham Hospital’s Charity Research Fund ENOS-2: ultra-acute (3-5 hours) stroke, currently 18 of 120 participants from 1 sites in UK – recruiting; CI Bath. The trial is testing the feasibility of recruiting patients with ultra-acute stroke within 3-5 hours of onset since this subgroup benefitted in ENOS.
Health Technology Assessment-funded PhEAST: recent (4-31 days) stroke and clinical dysphagia, currently 30 of 800 participants from 50 sites in 4 countries; CI: Bath. The trial is assessing whether Pharyngeal Electrical Stimulation (PES) is safe and effective at improving post-stroke dysphagia (PSD).
Health Technology Assessment-funded TICH-3: acute haemorrhagic stroke, currently 100 of 5500 participants from 145 sites in 11 countries; CI: Sprigg. This trial is testing the repurposing of tranexamic acid, a treatment for surgical bleeding, as a potential treatment for acute intracerebral haemorrhage.
Health Technology Assessment-funded MAPS-2: acute stroke, currently 108 of 2100 participants from 90 sites in UK; CI: Roffe. This trial is testing the reduction whether this treatment can reduce mortality and improve functional outcome.
NIHR Efficacy and Mechanism Evaluation-funded RECAST-3: hyperacute ischaemic stroke, aims to recruit 1300 participants in UK; CI: England. This trial will assess remote ischaemic per-conditioning in patients with hyperacute ischaemic stroke.
These trials include older patients, and use bespoke software for data collection, SAE and imaging adjudication.
Main tasks attributed in the project:
UNOTT led WP7 Statistical Analysis.